real-time news and commentary for investors
Friday, Sep 20
Japan takes opposite course to FDA over GSK-Theravance lung drug
- Japan has approved GlaxoSmithKline's (GSK) and Theravance's (THRX) inhaled lung drug Relvar for treating asthma but not chronic obstructive pulmonary disease (COPD).
- That's the opposite of Relvar's status in the U.S., where it can be used for COPD but not asthma.
- Japan's authorization comes a day after the medicine received a recommendation in the EU to be used for both conditions.
- Following Japan's decision, Theravance will make a $10M milestone payment to GSK. (PR)